Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Anticancer Therapy to Target Cancer Cells' Elevated Need for Heme

By LabMedica International staff writers
Posted on 04 Jul 2013
Cancer cells have metabolic requirements that separate them from normal cells, and render them vulnerable to drugs that target these processes.

A recent study aimed to identify bioenergetic alterations in lung cancer cells by directly measuring and comparing key metabolic activities in a pair of cell lines representing normal and non-small-cell lung cancer (NSCLC) cells developed from the same patient. More...
Lung cancer is the leading cause of cancer-related mortality in the US and worldwide and about 85% of the cases are NSCLC.

Investigators at the University of Texas (Dallas, USA) worked with a pair of cell lines representing normal nonmalignant HBEC (HBEC30KT) and NSCLC (HCC4017) cells developed from the same patient. They compared the metabolic and molecular profiles of this matched pair of cell lines grown under identical conditions.

Results published in the May 21, 2013, online edition of the journal PLOS ONE revealed that the rates of oxygen consumption and heme biosynthesis were intensified in NSCLC cells. Additionally, the NSCLC cells exhibited substantially increased levels of an array of proteins promoting heme synthesis, uptake, and function. The levels of oxygen-utilizing hemoproteins, such as cytoglobin, were dramatically increased in the cancer cells.

Inhibition of heme with succinyl acetone, a chemical that prevents cells from synthesizing heme, suppressed oxygen consumption, cancer cell proliferation, colony formation, and migration.

"Cancer cells not only make significantly more heme, we also found they uptake more heme from the blood," said senior author Dr. Li Zhang, professor of molecular and cell biology at the University of Texas. "All cells need a certain level of heme, but our findings indicate that normal cells need much less heme compared to cancer cells. We think a high level of heme in cancer cells results in a lot more hemoproteins, which metabolize oxygen and produce more cellular energy. That then drives the cancer cells to proliferate, to migrate, and to form colonies."

"When you inhibit heme synthesis or deplete heme, it does not affect normal cells too much," said Dr. Zhang. "It selectively affects cancer cells. That is the beauty of our work. Because inhibiting heme effectively arrested the progression of lung cancer cells, our findings could positively impact research on lung cancer biology and therapeutics."

Related Links:

University of Texas





Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.